Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity

Richard A. Drachtman, Peter D. Cole, Carla B. Golden, S. Jill James, Stepan Melnyk, Joseph Aisner, Barton A. Kamen

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

Methotrexate-induced neurotoxicity (MTX-Ntox) is a frequent complication of methotrexate (MTX) therapy for patients with both malignant and inflammatory diseases. MTX-Ntox can occur after intrathecal MTX or after low-, intermediate-, or high-dose systemic administration: Symptoms can present in the acute, subacute, or late setting form, and can range from affective disorders, malaise, and headaches, to somnolence, focal neurologic deficits, and seizures. While the pathogenesis of MTX-Ntox is likely multifactorial, one potential biochemical pathway leading from MTX to neurotoxicity involves the folate dependent remethylation of homocysteine (Hcy). MTX therapy is known to cause elevations of both plasma and CSF Hcy. Hcy is directly toxic to vascular endothelium and it and its metabolites are excitatory agonists of the N -methyl-D-aspartate (NMDA) receptor. Competitive or noncompetitive antagonists might afford protection from or reversal of MTX-Ntox. Using high-performance liquid chromatography (HPIC) with coulometric eletrochemical detection, the authors measured CSF Hcy in sequential patients with severe subacute MTX-Ntox. CSF Hcy was higher in these patients (n = 9, median = 0. 93 μM) than in asymptomatic patients (n = 11, median 0.2 μM, p < .01). Five patients with severe subacute MTX-Ntox (most with dysarthria and/or hemiplegia) were treated with 1-2 mg/kg oral dextromethorphan (DM), a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. All five had resolution of symptoms. These data provide additional clinical support for elevated CSF Hcy in the induction of MTX-Ntox through activation of the NMDA-receptor. These data provide support for a placebo-controlled clinical trial to examine the ability of DM to prevent or alleviate MTX-Ntox.

Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalPediatric Hematology and Oncology
Volume19
Issue number5
DOIs
StatePublished - Jun 25 2002

Keywords

  • Dextromethorphan
  • Methotrexate
  • Neurotoxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Drachtman, R. A., Cole, P. D., Golden, C. B., James, S. J., Melnyk, S., Aisner, J., & Kamen, B. A. (2002). Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatric Hematology and Oncology, 19(5), 319-327. https://doi.org/10.1080/08880010290057336